Day: December 30, 2019

SHANGHAI, China, Dec. 30, 2019 (GLOBE NEWSWIRE) — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced that it has priced its initial public offering of 11,500,000 American depositary shares (“ADSs”) at a price to the public of US$5.38 per ADS for a total offering size of approximately US$61.87 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents three Class A ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Stock Market today under the ticker symbol “MKD.”The Company has granted to the underwriters an option, exercisable within 30 days from the date of the final prospectus,...

NEW YORK and VIENNA, Austria, Dec. 30, 2019 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the first patient has been dosed in a Phase 1/2 clinical trial (NCT04180215) of HB-201, an immunotherapy for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers. This trial is HOOKIPA’s first clinical trial in immuno-oncology.HB-201 is a TheraT® platform-based vector (replication attenuated) from the arenavirus family expressing a non-oncogenic but highly antigenic E6/E7 fusion protein from HPV16. In preclinical studies, HB-201 was observed to be highly immunogenic, resulting in a robust CD8+ T cell response as compared to...

Í viðhengi má finna áætlun Landsbankans um fjármögnun á markaði fyrir árið 2020.ViðhengiFjármögnunaráætlun 2020

Attached is a schedule of Landsbankinn‘s market funding for the year 2020.AttachmentFunding plan 2020

SALT LAKE CITY, Dec. 30, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic test by healthcare professionals to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor Lynparza® (olaparib).  Lynparza is marketed by AstraZeneca (LSE/OMX Nordic/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada.  BRACAnalysis CDx is the first and only FDA-approved genetic test for this indication.“The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing...

All co-primary endpoints achieved in both Phase 3 clinical trialsTwyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over timeAdditional data to be shared during the January 8th investor conference call and webcastNESS ZIONA, Israel, Dec. 30, 2019 (GLOBE NEWSWIRE) —  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an investigational, combination of microencapsulated tretinoin 0.1% and microencapsulated benzoyl peroxide 3% cream, which demonstrated statistically significant improvement on all co-primary endpoints in the treatment of patients with acne vulgaris. Twyneo was also found to be well-tolerated.The primary endpoints for both trials included: the proportion of patients who succeeded...

PRESS RELEASE 30 DECEMBER 2019Italeaf: The Board of Directors reviewed the state of negotiations with financial creditors and postponed the approval of the financial statements as at 31 December 2018 and the half-yearly financial report as at 30 June 2019The Board of Directors of Italeaf S.p.A. (“Italeaf” or the “Company”), a holding company active in the cleantech and smart innovation sectors, listed on Nasdaq First North, met today, following the approval of the update of the 2019-2022 Reorganization Plan and the Financial Manoeuvre that is part of it (the “Plan”), as communicated to the market on October 30, 2019, and examined the progress of negotiations underway with financial creditors, aimed at signing a restructuring agreement pursuant to Article 182 bis r.d. 267/42.Massimiliano Bonamini (a...

COMUNICATO STAMPA 30 DICEMBRE 2019Italeaf: Esaminato lo stato di avanzamento delle trattative con i creditori finanziari, rinvio dell’approvazione del bilancio al 31 dicembre 2018 e della relazione finanziaria semestrale al 30 giugno 2019Il Consiglio di Amministrazione di Italeaf S.p.A. (“Italeaf” o la “Società”), holding di partecipazione attiva nei settori cleantech e smart innovation, quotata al Nasdaq First North, riunitosi in data odierna, facendo seguito all’approvazione dell’aggiornamento del Piano di Risanamento 2019-2022 e della Manovra Finanziaria che ne è parte (il “Piano”), come comunicato al mercato in data 30 ottobre 2019, ha esaminato lo stato di avanzamento dei negoziati in corso con i creditori finanziari, finalizzati alla sottoscrizione di un accordo...

AB Klaipėdos nafta (hereinafter – the Company) hereby informs that the National Energy Regulatory Council (hereinafter – the Council) on 30 December 2019 set the upper limits of revenue level allowed to earn by the Company from liquefied natural gas (hereinafter – LNG) regasification service amounting to 36 287 300 EUR for the year 2020 and adopted decisions on fixed component of LNG regasification service price, i.e. established the price of 194.31 EUR/MWh/day/year. New tariff will be applicable from 1 January 2020.For more information about the resolution adopted by the Council, please visit the website www.regula.lt.Jonas Lenkšas, Chief Financial Officer, +370 694 80594.

AB „Klaipėdos nafta“ (toliau – Bendrovė) informuoja, kad Valstybinė energetikos reguliavimo taryba (toliau – Taryba) 2019 m. gruodžio 30 d. priėmė sprendimą dėl suskystintų gamtinių dujų (toliau – SGD) pakartotinio dujinimo pajamų viršutinės ribos, kuri 2020 m. yra lygi 36 287 300 Eur ir pakartotino dujinimo paslaugos kainos pastoviosios dalies, kuri sudaro 194,31 Eur/MWh/parą/metus. Naujas tarifas įsigalios nuo 2020 m. sausio 1 d.Daugiau informacijos apie priimtus nutarimus pateikiama Tarybos interneto tinklalapyje www.regula.lt.